Impact of Demodex Blepharitis on Patients: Results of the Atlas Trial (ASCRS Paper ID 81946); Mitchell A. Jackson, M.D., et al.

AJMC®: Does the prevalence of Demodex blepharitis found by Trattler and colleagues 1 match what you see in clinical practice? BRUJIC: The prevalence of Demodex blepharitis is interesting. Prior to ...

Tarsus Pharmaceuticals Inc. delivered higher-than-expected fourth quarter revenue driven by surging demand for its eyedrop Xdemvy. More than two years into commercial launch, sales of Xdemvy, the ...

AJMC ®: Demodex blepharitis has a high estimated prevalence in the United States. However, few US studies of this disease exist. Why is this disease so understudied here? JACKSON: The main reason ...

Please provide your email address to receive an email when new articles are posted on . Cases of anterior blepharitis that do not resolve with antibiotics may actually be caused by Demodex mites, ...

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...

Add Yahoo as a preferred source to see more of our stories on Google. Waking up with some gunk in your eyes is usually nothing to worry about. The scientific name for this crust is rheum, and it forms ...